Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer
一项针对复发性卵巢癌的 II 期概念验证研究,评估度伐利尤单抗和西地尼布联合或不联合奥拉帕尼的疗效
期刊:
影响因子:
doi:10.21203/rs.3.rs-7724642/v1
Lee, Jung-Min; Tabata, Junya; Huang, Tzu-Ting; Giudice, Elena; Ibanez, Kristen; Nair, Jayakumar; Warner, Aanika; Solarz, Britanny; Bolanos, Valentina; Redd, Bernadette; Sato, Nahoko; Rastogi, Shraddha; Lee, Sunmin; Shrestha, Roshan; Mitrophanov, Alexander; Lipkowitz, Stanley; Conlon, Kevin; Huang, Chien Chu